MX9704203A - Utilizacion de derivados de teofilina para el tratamiento y la profilaxis de estados de choque, nuevos compuestos de xantina y procedimiento para su preparacion. - Google Patents

Utilizacion de derivados de teofilina para el tratamiento y la profilaxis de estados de choque, nuevos compuestos de xantina y procedimiento para su preparacion.

Info

Publication number
MX9704203A
MX9704203A MX9704203A MX9704203A MX9704203A MX 9704203 A MX9704203 A MX 9704203A MX 9704203 A MX9704203 A MX 9704203A MX 9704203 A MX9704203 A MX 9704203A MX 9704203 A MX9704203 A MX 9704203A
Authority
MX
Mexico
Prior art keywords
compounds
treatment
teophyline
xantine
prophylaxis
Prior art date
Application number
MX9704203A
Other languages
English (en)
Other versions
MXPA97004203A (es
Inventor
Ulrich Gebert
Erhard Wolf
Elisabeth Defossa
Uwe Heinelt
Hiristo Anagnostopulos
Karl Rudolphi
John J Grome
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19622737A external-priority patent/DE19622737A1/de
Priority claimed from DE1996129815 external-priority patent/DE19629815A1/de
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of MXPA97004203A publication Critical patent/MXPA97004203A/es
Publication of MX9704203A publication Critical patent/MX9704203A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Los compuestos de la formula I: se adecuan como medicamentos para el tratamiento de estados de choque. Los compuestos de la formula VIII son compuestos intermedios en la preparacion de los compuestos de la formula I.
MX9704203A 1996-06-07 1997-06-06 Utilizacion de derivados de teofilina para el tratamiento y la profilaxis de estados de choque, nuevos compuestos de xantina y procedimiento para su preparacion. MX9704203A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19622737.2 1996-06-07
DE19622737A DE19622737A1 (de) 1996-06-07 1996-06-07 Verwendung von Theophyllinderivaten zur Behandlung und Prophylaxe von Schockzuständen, neue Xanthinverbindungen und Verfahren zu deren Herstellung
DE1996129815 DE19629815A1 (de) 1996-07-24 1996-07-24 Verwendung von Theophyllinderivaten zur Behandlung und Prophylaxe von Schockzuständen, neue Xanthinverbindungen und Verfahren zu deren Herstellung
DE19629815.6 1996-07-24

Publications (2)

Publication Number Publication Date
MXPA97004203A MXPA97004203A (es) 1998-04-01
MX9704203A true MX9704203A (es) 1998-04-30

Family

ID=26026372

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9704203A MX9704203A (es) 1996-06-07 1997-06-06 Utilizacion de derivados de teofilina para el tratamiento y la profilaxis de estados de choque, nuevos compuestos de xantina y procedimiento para su preparacion.

Country Status (26)

Country Link
US (1) US6214992B1 (es)
EP (1) EP0812844B1 (es)
JP (1) JP4156687B2 (es)
KR (1) KR100477177B1 (es)
CN (1) CN1066146C (es)
AR (1) AR007506A1 (es)
AT (1) ATE226583T1 (es)
AU (1) AU712277B2 (es)
BR (1) BR9703499A (es)
CA (1) CA2207120C (es)
CZ (1) CZ292205B6 (es)
DE (1) DE59708533D1 (es)
DK (1) DK0812844T3 (es)
ES (1) ES2185837T3 (es)
HU (2) HU225040B1 (es)
ID (1) ID19469A (es)
IL (1) IL120997A (es)
MX (1) MX9704203A (es)
MY (1) MY117910A (es)
NO (1) NO312400B1 (es)
NZ (1) NZ328017A (es)
PL (1) PL186576B1 (es)
PT (1) PT812844E (es)
RU (1) RU2201930C2 (es)
SI (1) SI0812844T1 (es)
TW (1) TW520285B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
FR2804867B1 (fr) * 2000-02-15 2002-09-20 Hoechst Marion Roussel Inc Application de derives de xanthine pour la preparation d'un medicament destine a la prevention ou au traitement de l'osteoporose
FR2804958B1 (fr) * 2000-02-15 2005-07-08 Hoechst Marion Roussel Inc Derives de xanthine, leur procede de preparation et les intermediaires de ce procede, leur application comme medicament et les compositions pharmaceutiques les renfermant
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
SI1509525T1 (sl) * 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
AR040232A1 (es) * 2002-05-31 2005-03-23 Schering Corp Proceso para preparar inhibidores de la xantina fosfodiesterasa v, y precursores de los mismos
CN112500413B (zh) * 2020-10-13 2024-03-01 安徽中医药大学 一类黄嘌呤芳酸醚衍生物，其制备方法及用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735898A (en) 1985-07-16 1988-04-05 The University Of Virginia Alumini Patents Foundation Monoclonal antibodies and method of identifying species using the same
US4904472A (en) * 1987-04-10 1990-02-27 The University Of Virginia Alumni Patent Foundation Use of adenosine antagonists in the treatment of bradyarrhythmias and mechanical dysfunction associated with cardiopulmonary resuscitation
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
JPH03167186A (ja) * 1989-11-24 1991-07-19 Hokuriku Seiyaku Co Ltd キサンチン誘導体及びその用途
US5036683A (en) * 1990-06-04 1991-08-06 Geuvjehizian Moushegh Y Steering wheel lock protector
DE4019571A1 (de) 1990-06-20 1992-01-02 Hoechst Ag Pharmazeutische kombinationspraeparate enthaltend cephalosporin- und xanthinderivate und deren verwendung
DE19540798A1 (de) * 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
HUP9701016A2 (hu) 1998-12-28
AU2469897A (en) 1997-12-11
AU712277B2 (en) 1999-11-04
CZ174397A3 (en) 1997-12-17
CN1066146C (zh) 2001-05-23
CA2207120A1 (en) 1997-12-07
HU225040B1 (en) 2006-05-29
EP0812844A3 (de) 1998-04-08
US6214992B1 (en) 2001-04-10
NO312400B1 (no) 2002-05-06
IL120997A0 (en) 1997-11-20
CA2207120C (en) 2007-05-08
EP0812844B1 (de) 2002-10-23
BR9703499A (pt) 1998-10-06
PL186576B1 (pl) 2004-01-30
SI0812844T1 (en) 2003-02-28
AR007506A1 (es) 1999-11-10
HU9701016D0 (en) 1997-07-28
NO972582D0 (no) 1997-06-06
NZ328017A (en) 2001-05-25
PT812844E (pt) 2003-03-31
ATE226583T1 (de) 2002-11-15
NO972582L (no) 1997-12-08
PL320413A1 (en) 1997-12-08
DK0812844T3 (da) 2003-02-17
EP0812844A2 (de) 1997-12-17
JPH1059969A (ja) 1998-03-03
CN1169993A (zh) 1998-01-14
MY117910A (en) 2004-08-30
KR100477177B1 (ko) 2005-09-30
IL120997A (en) 2001-06-14
TW520285B (en) 2003-02-11
DE59708533D1 (de) 2002-11-28
ES2185837T3 (es) 2003-05-01
RU2201930C2 (ru) 2003-04-10
JP4156687B2 (ja) 2008-09-24
HU224958B1 (en) 2006-04-28
HU0500865D0 (en) 2005-11-28
ID19469A (id) 1998-07-16
HUP9701016A3 (en) 2004-11-29
CZ292205B6 (cs) 2003-08-13
KR980008230A (ko) 1998-04-30

Similar Documents

Publication Publication Date Title
MX9707980A (es) Derivados de 4-aminoquinazolina, composiciones que los contienen, y uso de los mismos.
MY133732A (en) Sulfonylcarboxamide derivatives, process for their preparation and their use as medicines
YU29099A (sh) Derivati 2-(purin-9-il)-tetrahidrofuran-3,4-diola
AP2000002016A0 (en) 2-(Purin-9-yl) Tetrahydrofuran-3,4-diol derivatives.
MX9702865A (es) Agentes estrogenicos.
MY133392A (en) Novel substituted pyrazole derivatives
PL367814A1 (en) 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
MX9700885A (es) Nuevas heteroariloxazolidinonas.
BG103417A (en) Condensed pyrimidine bicyclic derivatives
AP2000001875A0 (en) 2-(Purin-9-yl)-tetrahydrofuran -3,4-diol derivatives.
MY119181A (en) Aryl pyrimidine derivatives
AP9701019A0 (en) Phenylamino-substituted tricycle derivatives.
MY136270A (en) Processes and intermediates for preparing anti-cancer compounds
AU4613999A (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
MY133027A (en) C-4"-substituted macrolide derivatives
MX9503529A (es) Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen.
ZA975439B (en) New pyridyl alkane acid amides.
IN2012DE00109A (es)
MX9704203A (es) Utilizacion de derivados de teofilina para el tratamiento y la profilaxis de estados de choque, nuevos compuestos de xantina y procedimiento para su preparacion.
PL362131A1 (en) Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same
PL346143A1 (en) Tan-1057 derivatives
UA66866C2 (uk) Синтез морфолінових похідних
HK1053109A1 (en) Substituted homopiperidinyl benzimidazole compounds, pharmaceutical compositions comprising the same, methods for preparing them and the use for the preparation of a medicament of them
HK1077303A1 (en) Hexacyclic compounds
MXPA03005374A (es) Carbazoles antitumorales.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees